VOSTALLY - (1MG/1ML ; Solution)

Generic Name	RAMIPRIL	**Innovator**	ROSEMONT PHARMS
Dosage	1MG/1ML ; Solution	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	VOSTALLY is an angiotensin converting enzyme (ACE) inhibitor indicated: • for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • In patients 55 years or older at high risk of developing a major cardiovascular event, VOSTALLY is indicated to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes . • In adult patients with post-myocardial infarction heart failure to reduce the risk of cardiovascular death and hospitalization for heart failure .		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.